Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS Research and Therapy
Published in: AIDS Research and Therapy 1/2005

Open Access 01-12-2005 | Hypothesis

Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?

Authors: Karen S Slobod, Chris Coleclough, Scott A Brown, John Stambas, Xiaoyan Zhan, Sherri Surman, Bart G Jones, Amy Zirkel, Pamela J Freiden, Brita Brown, Robert Sealy, Mattia Bonsignori, Julia L Hurwitz

Published in: AIDS Research and Therapy | Issue 1/2005

Login to get access

Abstract

Today, scientists are often encouraged to custom-design vaccines based on a particular country or clade. Here, we review the scientific literature and then suggest that the overwhelming endeavor to produce a unique vaccine for every world region or virus subtype may not be necessary.
Literature
1.
Perrin L, Kaiser L, Yerly S: Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis. 2003, 3: 22-27. 10.1016/S1473-3099(03)00484-5CrossRefPubMed
2.
Delwart EL, Orton S, Parekh B, Dobbs T, Clark K, Busch MP: Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retroviruses. 2003, 19 (12): 1065-1070. 10.1089/088922203771881149CrossRefPubMed
3.
Anderson JP, Rodrigo AG, Learn GH, Madan A, Delahunty C, Coon M: Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E. J Virol. 2000, 74 (22): 10752-10765. 10.1128/JVI.74.22.10752-10765.2000PubMedCentralCrossRefPubMed
4.
McClutchan FE, Carr JK, Murphy D, Piyasirisilp S, Gao F, Hahn B: Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. AIDS Res Hum Retroviruses. 2002, 18 (15): 1135-1140. 10.1089/088922202320567879CrossRefPubMed
5.
Thomson MM, Perez-Alvarez L, Najera R: Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis. 2002, 2 (8): 461-471. 10.1016/S1473-3099(02)00343-2CrossRefPubMed
6.
Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, Thomas R: Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses. 2003, 19 (2): 133-144. 10.1089/088922203762688649CrossRefPubMed
7.
Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D: Diversity considerations in HIV-1 vaccine selection. Science. 2002, 296 (5577): 2354-2360. 10.1126/science.1070441CrossRefPubMed
8.
Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N: Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol. 2003, 84: 361-368. 10.1099/vir.0.18738-0CrossRefPubMed
9.
Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C: Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?. J Virol. 2002, 76: 5435-5451. 10.1128/JVI.76.11.5435-5451.2002PubMedCentralCrossRefPubMed
10.
Hanke T, McMichael AJ: Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nature Medicine. 2000, 6: 951-955. 10.1038/79626CrossRefPubMed
11.
Agwale SM, Zeh C, Robbins KE, Odama L, Saekhou A, Edubio A: Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine. 2002, 20 (2131): 2139-
12.
Cao H, Mani I, Vincent R, Mugerwa R, Mugyenyi P, Kanki P: Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis. 2000, 182: 1350-1356. 10.1086/315868CrossRefPubMed
13.
Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol. 1996, 70: 427-444.PubMedCentralPubMed
14.
Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H: Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies – implications for acquired immunodeficiency syndrome vaccine. J Infect Dis. 2004, 189: 71-74. 10.1086/420833CrossRefPubMed
15.
D'Costa S, Slobod KS, Webster RG, White SW, Hurwitz JL: Structural features of HIV envelope defined by antibody escape mutant analysis. AIDS Res Hum Retroviruses. 2001, 17: 1205-1209. 10.1089/088922201316912808CrossRefPubMed
16.
Zhan X, Slobod KS, Surman S, Brown SA, Lockey TD, Coleclough C: Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. J Virol. 2003, 77: 4231-4236. 10.1128/JVI.77.7.4231-4236.2003PubMedCentralCrossRefPubMed
17.
Gonzales MJ, Delwart E, Rhee SY, Tsui R, Zolopa AR, Taylor J: Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis. 2003, 188: 397-405. 10.1086/376534PubMedCentralCrossRefPubMed
18.
Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A: Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol. 2004, 78: 94-103. 10.1128/JVI.78.1.94-103.2004PubMedCentralCrossRefPubMed
19.
Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT: HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature. 2002, 420: 434-439. 10.1038/nature01200CrossRefPubMed
20.
Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992, 258: 1938-1941.CrossRefPubMed
21.
Burns DPW, Desrosiers RC: Envelope sequence variation, neutralizing antibodies and primate lentivirus persistence. Curr Top Microbiol Immunol. 1994, 188: 185-219.PubMed
22.
Titti F, Sernicola L, Geraci A, Panzini G, Di Fabio S, Belli R: Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol. 1997, 78: 2529-2539.CrossRefPubMed
23.
Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV: Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1994, 7: 211-219.PubMed
24.
Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003, 100 (7): 4144-4149. 10.1073/pnas.0630530100PubMedCentralCrossRefPubMed
25.
Rencher SD, Slobod KS, Dawson D, Lockey TD, Hurwitz JL: Does the key to a successful HIV vaccine lie among the envelope sequences of infected individuals?. Aids Res Hum Retroviruses. 1995, 11: 1131-1133.CrossRefPubMed
26.
Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX: Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA. 2002, 287 (5): 606-611. 10.1001/jama.287.5.606CrossRefPubMed
27.
Nyambi PN, Nadas A, Mbah HA, Burda S, Williams C, Gorny MK: Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol. 2000, 74 (22): 10670-10680. 10.1128/JVI.74.22.10670-10680.2000PubMedCentralCrossRefPubMed
28.
Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden PJ: Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis. 2004, 23: 106-110. 10.1007/s10096-003-1075-3CrossRefPubMed
29.
Hurwitz JL, Slobod KS, Lockey TD, Wang S, Chou T-HW, Lu S: Application of the polyvalent approach to HIV-1 vaccine development. Current Drug Targets-Infectious Disorders. 2005
30.
Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B: Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine. 2005, 23: 2454-2464. 10.1016/j.vaccine.2004.10.030CrossRefPubMed
31.
Zhan X, Slobod KS, Surman S, Brown SA, Coleclough C, Hurwitz JL: Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells. Vaccine. 2004, 22: 1206-1213. 10.1016/j.vaccine.2003.09.028CrossRefPubMed
32.
Burnet FM: Poliomyelitis in the light of recent experimental work. Health Bulletin. Department of Health-Victoria, Australia. 1945
Metadata
Title
Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?
Authors
Karen S Slobod
Chris Coleclough
Scott A Brown
John Stambas
Xiaoyan Zhan
Sherri Surman
Bart G Jones
Amy Zirkel
Pamela J Freiden
Brita Brown
Robert Sealy
Mattia Bonsignori
Julia L Hurwitz
Publication date
01-12-2005
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2005
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-2-3

Other articles of this Issue 1/2005

AIDS Research and Therapy 1/2005 Go to the issue

Research

HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors

Research

Vitamin supplementation for prevention of mother-to-child transmission of HIV and pre-term delivery: a systematic review of randomized trial including more than 2800 women

Short report

HIV in semen: Still more to be learned

Research

Human immunodeficiency virus type-1 episomal cDNA in semen

Short report

Evaluation of the proficiency of trained non-laboratory health staffs and laboratory technicians using a rapid and simple HIV antibody test

Methodology

Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits